Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Exebacase
DRUG
2 trials
Sponsors
ContraFect
Conditions
Covid19
MRSA Bacteremia
MRSA Bloodstream Infection
MRSA Right-sided Endocarditis
Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Endocarditis
Phase 3
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
Terminated
NCT04160468
ContraFect
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Start: 2019-12-20
End: 2022-09-09
Updated: 2023-11-02
Unknown Phase
Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia
NCT04597242
ContraFect
Covid19, MRSA Bacteremia, MRSA Bloodstream Infection +1
Updated: 2022-08-31
Related Papers
Exebacase in Addition to Standard-of-Care Antibiotics for <i>Staphylococcus aureus</i> Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT)
Clinical Infectious Diseases
2024-01-31
35 citations
Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity
Journal of Clinical Microbiology
2021-04-29
16 citations